

# ESC Highlights 2024

[●] Recorded Live on:  
**September 10  
2024**



Developed by:



## ESC 2024 Highlights: OnDemand Webcast



**Milan Gupta,**  
MD, FRCPC, FCCS, CPC(HC)  
Assistant Professor, Department  
of Medicine, University of Toronto  
Medical Director, Collaborative  
CME and Research Network  
Brampton, ON



**Narendra Singh,**  
MD, FRCPC, FCCS, FACC, FAHA  
Director, NSC Cardiology  
Clinical Assistant Professor,  
Medical College of Georgia at  
Augusta University and Mercer  
University  
Atlanta, GA

This program was developed by CCRN and received an unrestricted educational grant from Alnylam Pharmaceuticals, Bayer Canada and Anthos Therapeutics.

This program covers key clinical trial findings and their implications from ESC 2024. This program is intended for cardiovascular specialists and primary care physicians.

### Discussion Topics:

- **HELIOS-B** - Vutrisiran for transthyretin cardiomyopathy
- **RESHAPE-HF2 and MATTERHORN** - The role of transcatheter mitral valve repair in patients with heart failure
- **OCEANIC-AF** - How does the factor XI inhibitor asundexian compare vs. apixaban in AF?
- **FINEARTS-HF** - What is the role of finerenone in HFpEF?
- **AZALEA-TIMI 71** - Factor XI inhibition and peri-procedural bleeding

### Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at ESC 2024
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



[www.ccrnmd.com](http://www.ccrnmd.com)

For program inquiries, please  
contact [info@ccrnmd.com](mailto:info@ccrnmd.com)



Watch the recording on CCRN website Here  
[www.ccrnmd.com](http://www.ccrnmd.com) > Education > Webcasts